Healthcare [ 11/13 ] | Biotechnology [ 91/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 8, 23 | -0.08 Increased by +71.43% | -0.08 |
| Aug 25, 23 | -0.06 Decreased by -126.09% | -0.02 Decreased by -200% |
| May 8, 23 | -0.14 Increased by +60% | -0.15 Increased by +6.67% |
| Mar 9, 23 | -0.04 Increased by +90% | -0.19 Increased by +78.95% |
| Nov 3, 22 | -0.28 Increased by +17.65% | -0.15 Decreased by -86.67% |
| Aug 4, 22 | 0.23 Increased by +145.1% | -0.31 Increased by +174.19% |
| May 9, 22 | -0.35 Increased by +22.22% | -0.29 Decreased by -20.69% |
| Mar 1, 22 | -0.4 Increased by +33.33% | -0.33 Decreased by -21.21% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 42.05 M Decreased by -14.13% | -14.49 M Increased by +74% | Decreased by -34.46% Increased by +69.73% |
| Jun 30, 23 | 56.38 M Decreased by -55.53% | -11.17 M Decreased by -138.16% | Decreased by -19.82% Decreased by -185.8% |
| Mar 31, 23 | 40.13 M Decreased by -34.96% | -16.74 M Increased by +74.77% | Decreased by -41.71% Increased by +61.21% |
| Dec 31, 22 | 55.18 M Decreased by -7.42% | -8.76 M Increased by +87.61% | Decreased by -15.87% Increased by +86.62% |
| Sep 30, 22 | 48.96 M Increased by +0.43% | -55.74 M Increased by +6.4% | Decreased by -113.83% Increased by +6.79% |
| Jun 30, 22 | 126.76 M Increased by +139.56% | 29.28 M Increased by +135.26% | Increased by +23.1% Increased by +114.72% |
| Mar 31, 22 | 61.7 M Increased by +17.96% | -66.35 M Increased by +4.64% | Decreased by -107.54% Increased by +19.16% |
| Dec 31, 21 | 59.6 M Increased by +5.13% | -70.68 M Increased by +18.76% | Decreased by -118.58% Increased by +22.72% |
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.